van der HeijdeDCheng-Chung WeiJDougadosM, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441-2451. doi:10.1016/S0140-6736(18)31946-9
2.
NashPKirkhamBOkadaM, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317-2327. doi:10.1016/S0140-6736(17)31429-0
3.
AzadehHAlizadeh-NavaeiRRezaiemaneshARajabinejadM.Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: a systematic review and meta-analysis. Inflammopharmacology. 2022;30(2):435-451. doi:10.1007/s10787-022-00933-z
4.
ShanshalMEbadianM.Serum sickness. N Engl J Med. 2023;389(8):749. doi:10.1056/NEJMicm2216266
5.
SurdackiMFernandezEPhillipsEJStoneCAJr.Drugs associated with serum sickness and serum sickness-like reactions: a review of FDA Adverse Event Reporting System (FAERS) data. J Allergy Clin Immunol Pract. 2024;12(5):1351-1354. doi:10.1016/j.jaip.2024.03.006
6.
DeodharABlauveltALebwohlM, et al. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials. Arthritis Res Ther. 2024;26(1):49. doi:10.1186/s13075-023-03257-7
7.
ChandranVvan der HeijdeDFleischmannRM, et al. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology (Oxford). 2020;59(10):2774-2784. doi:10.1093/rheumatology/kez684
8.
BlauveltALebwohlMGMabuchiT, et al. Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2021;85(2):360-368. doi:10.1016/j.jaad.2020.11.022
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
